Physician profile
Ryan K Deibert
NPI 1588896104
$4,184.07
in general payments reported to CMS, 2019-2025
11 companies · $1,599 in 2025
The $1,599 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2021: $115 · 2022: $122 · 2023: $484 · 2024: $1,516 · 2025: $1,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,673 · Travel and Lodging: $855 · Entertainment: $70.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,673.28 |
| Travel and Lodging | $855.36 |
| Entertainment | $70.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,981.05 | 2019-2025 | Total30, Precision7, Dailies Total1 |
| Lumenis Be INC | $848.78 | 2025 | M22 |
| Tarsus Pharmaceuticals, INC. | $248.74 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $246.81 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $237.08 | 2019 | |
| Bausch & Lomb Americas INC. | $128.30 | 2025 | Vyzulta |
| Horizon Therapeutics Plc | $121.83 | 2022 | |
| Rxsight INC | $118.47 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Allergan, INC. | $115.00 | 2021 | |
| Optos, INC. | $70.70 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Astellas Pharma US INC | $67.31 | 2023 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Deibert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.